Protagonist Therapeutics, Inc.
PTGX
Rank in Stocks
#2241
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Share Price
$138.50
Market Cap
$8.96B
Change (1 day)
3.02%
Change (1 year)
80.53%
Country
US
Trade Protagonist Therapeutics, Inc. (PTGX)
Category
Healthcare
P/E ratio for Protagonist Therapeutics, Inc. (PTGX)
P/E ratio as of October 2026 TTM: 111.88
According to Protagonist Therapeutics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 111.88. At the end of 2023 the company had a P/E ratio of -16.49.
P/E ratio history for Protagonist Therapeutics, Inc. from 2014 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 111.88 | 1,194.90% |
| 2024 | 8.64 | -152.39% |
| 2023 | -16.49 | 280.25% |
| 2022 | -4.34 | -66.44% |
| 2021 | -12.92 | 23.24% |
| 2020 | -10.48 | 343.22% |
| 2019 | -2.37 | -38.84% |
| 2018 | -3.87 | -61.17% |
| 2017 | -9.96 | 158.95% |
| 2016 | -3.85 | -17.01% |
| 2015 | -4.63 | -25.48% |
| 2014 | -6.22 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -74.27% |
US
|
|
| -28.36 | -125.35% |
US
|
|
| -24.57 | -121.96% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -72.89% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.